New daily adaptive radiation aims to cut side effects in prostate cancer patients
NCT ID NCT05830838
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new radiation technique for men whose prostate cancer returns after surgery. Instead of many standard treatments, this approach uses daily scans to adjust the radiation beam precisely, potentially reducing side effects and shortening the number of sessions. About 50 participants will be followed to see if the method is safe and tolerable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
50 people
The number who actually took part.
- Started
-
Jul 2023
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males age \>= 18 years who are receiving post-operative radiation therapy to the prostate fossa, with or without inclusion of the pelvic lymph nodes, for biochemical recurrences after radical prostatectomy. * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) =\< 2. * Ability to complete questionnaire(s) by themselves or with assistance. * Provide written informed consent. * Willingness and ability to complete protocol-specified follow-up (during the active monitoring phase of the study). Exclusion Criteria: * Current evidence of untreated metastatic prostate cancer involving nonregional lymph nodes outside of the bony pelvis, bone, or visceral organs. * Receipt of cytotoxic chemotherapy within 3 months prior to enrollment. * Prior radiation therapy to pelvis such that the proposed study treatment volume received 10 Gy or greater. * Co-morbid severe concurrent disease that would result in a life expectancy of \< 5 years. * Diabetes mellitus-associated vascular ulcers or wounding healing problems, inflammatory bowel disease, or a diagnosed connective tissue disorder. * Medical or psychiatric conditions that preclude informed decision-making or adherence to study protocols. * Men of childbearing potential who are unwilling to employ adequate contraception. * History of a bladder neck contracture, urethral stricture that required dilation, or any surgical repair/reconstruction involving the bladder or urethra other than radical prostatectomy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Malignant prostate neoplasm are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States